|Bid||41.72 x 1400|
|Ask||49.94 x 800|
|Day's Range||47.73 - 50.56|
|52 Week Range||38.41 - 79.81|
|Beta (5Y Monthly)||0.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||71.13|
Axonics (AXNX) delivered earnings and revenue surprises of 27.54% and 7.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
IRVINE, Calif., May 05, 2022--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2022.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...